LixiLan-O and DUAL Studies in Type 2 Diabetes

Rodolfo J. Galindo, MD:The first study I’d like to explain is the LixiLan-O, which was 1 of the first studies done. It was published by Dr Melanie Davies, et al.…

UC Davis researchers find dual cytokine blockage as a novel treatment against graft-versus-host disease in blood stem cell transplantations

Cytokines TNF and IL-6 can cause severely damaging inflammatory effects as a result of stem cells attacking host cells of blood cancer patients By BRANDON NGUYEN — [email protected]  Researchers at…